Virtual Library
Start Your Search
Y. Yoshida
Author of
-
+
P2.07 - Immunology and Immunotherapy (ID 708)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.07-014 - Immune Checkpoint Inhibitors for Brain Metastases of Non-Small-Cell Lung Cancer (ID 8211)
09:30 - 09:30 | Author(s): Y. Yoshida
- Abstract
Background:
Immune checkpoint inhibitors have shown clinical efficacy in non-small-cell lung cancer (NSCLC). However, data for efficacy in brain metastasis is limited because patients with untreated brain metastases were excluded in clinical trials.
Method:
We retrospectively evaluated NSCLC patients with brain metastases who had received immune checkpoint inhibitors at Chiba Cancer Center between January 2016 and May 2017.
Result:
Eighteen patients were eligible for this study. Of these, ten were men, and eight were women; median age was 56 years (range, 32–75 years). Fourteen patients had adenocarcinoma, three had squamous cell carcinoma, and one had a transformation from adenocarcinoma to squamous cell carcinoma. Surgery and whole brain radiation was previously performed in four patients each, while stereotactic radiosurgery was performed in nine patients. Four patients were not treated with local brain therapy. Sixteen patients were treated with nivolumab, while two patients were treated with pembrolizumab. Among 16 patients who had assessable brain metastases, one (6%) had a complete response (CR), ten (63%) had a stable disease (SD), and five (31%) had a progressive disease (PD). Among four patients with locally untreated brain metastases, there was one (25%) each with CR and SD, while two (50%) had PD. Seven (44%) patients had worsening of cerebral edema, including one who was treated with glucocorticoids. Immune checkpoint inhibitors had to be stopped in four patients due to worsening of brain metastases; two of them were treated again with immune checkpoint inhibitors after stereotactic radiosurgery.
Conclusion:
Immune checkpoint inhibitors have the potential to improve brain metastases of NSCLC; however, caution needs to be exercised for worsening of cerebral edema in some cases.
